Ongoing Clinical Trials for Ocular Lymphoma
Currently, there is 1 ongoing clinical trial for ocular lymphoma, specifically focusing on ocular adnexal marginal zone lymphoma. This trial is investigating the use of an antibiotic treatment to target a bacterial infection that may be linked to this rare form of eye cancer.
Clinical trial locations
Study on the Effectiveness of Doxycycline for Treating Newly Diagnosed Ocular Adnexal Marginal Zone Lymphoma Patients
This clinical trial is exploring a new approach to treating a specific type of cancer that affects the tissues around the eyes, called Ocular Adnexal Marginal Zone Lymphoma (OAMZL). The study is being conducted in Italy and focuses on using an antibiotic called doxycycline to treat patients who have been newly diagnosed with this condition.
Main focus and goal: The trial investigates whether doxycycline can effectively treat OAMZL by eliminating a bacteria called Chlamydophila psittaci, which researchers believe may be connected to the development of this type of lymphoma. The treatment involves taking doxycycline over an extended period, with careful monitoring to see if the bacterial infection is successfully cleared. If the infection returns, patients will receive another round of antibiotic treatment. The primary goal is to achieve what doctors call “progression-free survival” for 2 years, meaning the cancer does not worsen during this time.
Who can participate: The trial is open to adults over 18 years old who have been newly diagnosed with OAMZL affecting the eye area, including the conjunctiva, tear glands, or soft tissues around the eye. Patients must have a single or double lesion (stage IE) and not have received any previous treatment for this condition. Participants need to have adequate bone marrow, kidney, and liver function, and must test negative for HIV, Hepatitis B, and Hepatitis C. They should have a performance status score (ECOG PS) of 0-2, which measures their ability to carry out daily activities. Additionally, patients must not have taken any antibiotics in the 3 months before joining the study and must agree to use effective birth control if sexually active and able to have children.
Who cannot participate: The trial excludes patients who do not have a newly diagnosed OAMZL, those who are pregnant or breastfeeding, and anyone who is allergic to the study medications. Patients participating in another clinical trial at the same time, those with other medical conditions that could interfere with the study, or those unable to follow the study procedures cannot join. Additionally, people with certain symptoms like fever, night sweats, and weight loss (known as B symptoms) are not eligible.
Investigational drug: The antibiotic being tested is doxycycline, which is taken by mouth in tablet or capsule form. This medication works by stopping bacteria from making proteins they need to grow and reproduce. While doxycycline is already an approved antibiotic used for various infections, this trial is studying whether it can be effective specifically for treating OAMZL by targeting the Chlamydophila psittaci infection believed to be associated with this type of lymphoma.
Throughout the study, researchers will monitor how well patients tolerate the treatment, track infection eradication rates, and observe overall survival. They will also examine genetic aspects of the lymphoma to better understand potential links between the bacterial infection and the cancer.
Summary
Currently, only one clinical trial is actively recruiting patients with ocular lymphoma, specifically focusing on ocular adnexal marginal zone lymphoma. This trial, located in Italy, represents an innovative approach by investigating whether an antibiotic treatment can effectively address this rare cancer by targeting a potentially associated bacterial infection. The study reflects growing interest in understanding the relationship between certain infections and lymphoma development, and whether treating the infection might help control the cancer. Patients interested in this trial should discuss with their healthcare providers whether they meet the eligibility criteria and if participation might be appropriate for their individual situation.
